Antiviral aliphatic ester prodrugs of tenofovir
US10519159B2 · kind B2 · utility
4Cited by
11References
22Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 20, 2017 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | Dec 20, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.